163 related articles for article (PubMed ID: 29733873)
21. A Double Negative Loop Comprising ETV6/RUNX1 and MIR181A1 Contributes to Differentiation Block in t(12;21)-Positive Acute Lymphoblastic Leukemia.
Yang YL; Yen CT; Pai CH; Chen HY; Yu SL; Lin CY; Hu CY; Jou ST; Lin DT; Lin SR; Lin SW
PLoS One; 2015; 10(11):e0142863. PubMed ID: 26580398
[TBL] [Abstract][Full Text] [Related]
22. The enhancer RNA
Tan SH; Leong WZ; Ngoc PCT; Tan TK; Bertulfo FC; Lim MC; An O; Li Z; Yeoh AEJ; Fullwood MJ; Tenen DG; Sanda T
Blood; 2019 Jul; 134(3):239-251. PubMed ID: 31076442
[TBL] [Abstract][Full Text] [Related]
23. Runx1 is essential at two stages of early murine B-cell development.
Niebuhr B; Kriebitzsch N; Fischer M; Behrens K; Günther T; Alawi M; Bergholz U; Müller U; Roscher S; Ziegler M; Buchholz F; Grundhoff A; Stocking C
Blood; 2013 Jul; 122(3):413-23. PubMed ID: 23704093
[TBL] [Abstract][Full Text] [Related]
24. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.
Grossmann V; Kern W; Harbich S; Alpermann T; Jeromin S; Schnittger S; Haferlach C; Haferlach T; Kohlmann A
Haematologica; 2011 Dec; 96(12):1874-7. PubMed ID: 21828118
[TBL] [Abstract][Full Text] [Related]
25. Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1.
Tijchon E; van Emst L; Yuniati L; van Ingen Schenau D; Gerritsen M; van der Meer LT; Williams O; Hoogerbrugge PM; Scheijen B; van Leeuwen FN
Exp Hematol; 2018 Apr; 60():57-62.e3. PubMed ID: 29408281
[TBL] [Abstract][Full Text] [Related]
26. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL.
Grossmann V; Haferlach C; Weissmann S; Roller A; Schindela S; Poetzinger F; Stadler K; Bellos F; Kern W; Haferlach T; Schnittger S; Kohlmann A
Genes Chromosomes Cancer; 2013 Apr; 52(4):410-22. PubMed ID: 23341344
[TBL] [Abstract][Full Text] [Related]
27. APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
Li Z; Abraham BJ; Berezovskaya A; Farah N; Liu Y; Leon T; Fielding A; Tan SH; Sanda T; Weintraub AS; Li B; Shen S; Zhang J; Mansour MR; Young RA; Look AT
Leukemia; 2017 Oct; 31(10):2057-2064. PubMed ID: 28260788
[TBL] [Abstract][Full Text] [Related]
28. Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma.
Kundu M; Compton S; Garrett-Beal L; Stacy T; Starost MF; Eckhaus M; Speck NA; Liu PP
Blood; 2005 Nov; 106(10):3621-4. PubMed ID: 16051740
[TBL] [Abstract][Full Text] [Related]
29. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL.
Della Gatta G; Palomero T; Perez-Garcia A; Ambesi-Impiombato A; Bansal M; Carpenter ZW; De Keersmaecker K; Sole X; Xu L; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Meijerink JP; Califano A; Ferrando AA
Nat Med; 2012 Feb; 18(3):436-40. PubMed ID: 22366949
[TBL] [Abstract][Full Text] [Related]
30. Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.
Ter Elst A; Ma B; Scherpen FJ; de Jonge HJ; Douwes J; Wierenga AT; Schuringa JJ; Kamps WA; de Bont ES
Cancer Res; 2011 Apr; 71(7):2761-71. PubMed ID: 21447743
[TBL] [Abstract][Full Text] [Related]
31. Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia.
Jakobczyk H; Debaize L; Soubise B; Avner S; Rouger-Gaudichon J; Commet S; Jiang Y; Sérandour AA; Rio AG; Carroll JS; Wichmann C; Lie-A-Ling M; Lacaud G; Corcos L; Salbert G; Galibert MD; Gandemer V; Troadec MB
J Hematol Oncol; 2021 Mar; 14(1):47. PubMed ID: 33743795
[TBL] [Abstract][Full Text] [Related]
32. Regulatory mechanisms and context-dependent roles of TAL1 in T-cell acute lymphoblastic leukemia.
Ong JZL; Tan TK; Wang L; Tan SH; Sanda T
Haematologica; 2024 May; 109(5):1359-1372. PubMed ID: 37855064
[TBL] [Abstract][Full Text] [Related]
33. Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia.
Aoki K; Hyuga M; Tarumoto Y; Nishibuchi G; Ueda A; Ochi Y; Sugino S; Mikami T; Kobushi H; Kato I; Akahane K; Inukai T; Takaori-Kondo A; Takita J; Ogawa S; Yusa K
Blood; 2024 Feb; 143(7):604-618. PubMed ID: 37922452
[TBL] [Abstract][Full Text] [Related]
34. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
Fu L; Shi J; Liu A; Zhou L; Jiang M; Fu H; Xu K; Li D; Deng A; Zhang Q; Pang Y; Guo Y; Hu K; Zhou J; Wang Y; Huang W; Jing Y; Dou L; Wang L; Xu K; Ke X; Nervi C; Li Y; Yu L
Int J Cancer; 2017 Feb; 140(3):653-661. PubMed ID: 27770540
[TBL] [Abstract][Full Text] [Related]
35. RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome.
Rooney N; Mason SM; McDonald L; Däbritz JHM; Campbell KJ; Hedley A; Howard S; Athineos D; Nixon C; Clark W; Leach JDG; Sansom OJ; Edwards J; Cameron ER; Blyth K
Cancer Res; 2020 Jun; 80(11):2325-2339. PubMed ID: 32156779
[TBL] [Abstract][Full Text] [Related]
36. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
37. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.
Cunningham L; Finckbeiner S; Hyde RK; Southall N; Marugan J; Yedavalli VR; Dehdashti SJ; Reinhold WC; Alemu L; Zhao L; Yeh JR; Sood R; Pommier Y; Austin CP; Jeang KT; Zheng W; Liu P
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14592-7. PubMed ID: 22912405
[TBL] [Abstract][Full Text] [Related]
38. MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes TAL1 in T-Cell Acute Lymphoblastic Leukemia.
Sun H; Zhang Z; Luo W; Liu J; Lou Y; Xia S
Technol Cancer Res Treat; 2020; 19():1533033820934130. PubMed ID: 32633635
[TBL] [Abstract][Full Text] [Related]
39. Rictor/mammalian target of rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3.
Hua C; Guo H; Bu J; Zhou M; Cheng H; He F; Wang J; Wang X; Zhang Y; Wang Q; Zhou J; Cheng T; Xu M; Yuan W
Exp Hematol; 2014 Dec; 42(12):1031-40.e1-4. PubMed ID: 25201756
[TBL] [Abstract][Full Text] [Related]
40. Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.
Borland G; Kilbey A; Hay J; Gilroy K; Terry A; Mackay N; Bell M; McDonald A; Mills K; Cameron E; Neil JC
Oncotarget; 2016 Apr; 7(17):22973-87. PubMed ID: 27056890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
